Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Master Transcription Regulators02:23

Master Transcription Regulators

7.7K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How Moral Resilience Shapes Oncology Nurses' Responses to Ethical Challenges: A Mixed-Methods Study.

Cancer nursing·2026
Same author

Eldecalcitol and calcium supplementation in Chinese women with postmenopausal osteoporosis: a prospective observational cohort study.

Journal of bone and mineral metabolism·2026
Same author

The disease burden of inguinal, femoral, and abdominal hernias in children from low- and middle-income countries, 1990-2023 with projections to 2050: a systematic analysis of the Global Burden of Disease Study.

Translational pediatrics·2026
Same author

Health-related quality of life and caregiver burden in Chinese families with disorders of sex development: a person-centered analysis.

European journal of pediatrics·2026
Same author

Curcumin as a multi-target therapy for osteoarthritis in rats: a systematic review and meta-analysis.

Inflammopharmacology·2026
Same author

Structural basis of the AlgU-MucA<sup>cyto</sup> interaction and SspB-mediated degradation in <i>Pseudomonas aeruginosa</i> stress response.

mBio·2026

Related Experiment Video

Updated: Jan 18, 2026

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.8K

MEF2C is a potential prognostic biomarker for osteosarcoma.

Zhihui Zheng1, Zhicheng Liao, Liang Pang

  • 1Department of Orthopedic Surgery, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou, China.

Medicine
|September 9, 2025
PubMed
Summary

This study identified MEF2C as a key gene associated with osteosarcoma (OS) risk. MEF2C shows potential as a prognostic biomarker for osteosarcoma, aiding in treatment strategies.

Keywords:
Mendelian randomization analysisdifferentially expressed genesexpression quantitative trait lociosteosarcoma

More Related Videos

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.6K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.2K

Related Experiment Videos

Last Updated: Jan 18, 2026

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.8K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.6K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.2K

Area of Science:

  • Oncology
  • Genetics
  • Bioinformatics

Background:

  • Osteosarcoma (OS) is a primary bone cancer with complex genetic underpinnings.
  • Identifying novel therapeutic targets and genetic factors is crucial for improving OS treatment outcomes.

Purpose of the Study:

  • To investigate potential therapeutic targets for osteosarcoma (OS) using bioinformatics methods.
  • To identify genetic factors influencing OS treatment and prognosis.

Main Methods:

  • Processed three OS gene expression datasets from the Gene Expression Omnibus database.
  • Screened for differentially expressed genes (DEGs) and performed enrichment analysis.
  • Utilized Mendelian randomization, expression quantitative trait loci, and genome-wide association study data to identify key genes, including MEF2C, followed by validation and survival analyses.

Main Results:

  • Identified 269 DEGs, with enrichment analysis highlighting roles in extracellular matrix organization and ossification.
  • Mendelian randomization identified MEF2C as significantly associated with OS.
  • Validation confirmed elevated MEF2C expression in OS tissues; MEF2C correlated with high-risk OS, immune cell activity, and demonstrated prognostic value for overall and event-free survival.

Conclusions:

  • MEF2C is significantly associated with increased osteosarcoma risk.
  • MEF2C holds potential as a prognostic biomarker for osteosarcoma.
  • Further investigation into MEF2C and its related genes (e.g., APOE, SOX18) may reveal new therapeutic strategies for OS.